0947 GMT - Innovent Biologics's newly approved weight-loss drug could begin to bring in revenue in 2H, Morningstar analyst Yurou Zheng says in a research note. Innovent secured approval last week in China for its weight-loss drug mazdutide. The analyst thinks the near-term challenge for mazdutide, or weight-loss drugs in general, is potential price competition. Users will likely pivot to cheaper options if the efficacy profiles are similar or even slightly less superior, the analyst says. "Over the long term, a bigger challenge for the industry would be coming up with the next generation weight loss drug, especially for orally administered ones with an emphasis on the small molecule modality for greater effect," she adds.(sherry.qin@wsj.com)

(END) Dow Jones Newswires

June 30, 2025 05:47 ET (09:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.